CSI Market
Sign In | Register

Momenta Pharmaceuticals inc (MNTA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access MNTA Annual Cash Flow →
This cash flow overview for Momenta Pharmaceuticals inc spans from Jun 30 2019 to Jun 30 2020, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2020)
6 Months 		(Mar 31 2020) (Dec 31 2019) (Sep 30 2019) (Jun 30 2019)
Operating Activities
Income-96.59
Depreciation & amortization1.55
Amortization of Other Assets0.58
Increase (Decrease) in Deferred Revenue0.00
Increase (Decrease) in Restructuring Reserve0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property-0.02
Share-based Compensation24.24
Income (Loss) from Equity Method Investments0.00
Increase (Decrease) in Restricted Cash for Operating Activities0.00
Gain Loss On Disposition Of Property-
Equity Method Investment Other Than Temporary Impairment-
Increase Decrease Collaboration Payable-1.92
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value-
Increase Decrease In Collaboration Receivable1.41
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-9.44
Increase (Decrease) in Accrued Liabilities-22.23
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-4.99
Other Working Capital1.89
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.16
Discontinued operations0.00
Net Cash flow from Operating Activities-105.69
Investing Activities
Capital Expenditures-1.73
Sale of Capital Items0.04
Proceeds from Sale and Maturity of Available-for-sale Securities129.52
Payments to Acquire Available-for-sale Securities, Debt-225.67
Real Estate Investments0.00
Payments For Assets Acquired Under Purchase Agreement-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-97.84
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.26
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock12.41
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-384.36
Payments On Financed Leasehold Improvements-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents384.36
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities12.14
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-107.38
Total Cash Flow-191.39
4 historic quarters locked

Sign in to unlock the full Momenta Pharmaceuticals inc cash flow history.

Sign In Create Free Account

About MNTA Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.